4.7 Article

Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation

Journal

FREE RADICAL BIOLOGY AND MEDICINE
Volume 47, Issue 8, Pages 1205-1211

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2009.07.033

Keywords

Necrotizing enterocolitis; Inflammatory bowel disease; Inflammation; Reactive oxygen species; Probiotics; Lactobacillus; Free radicals

Funding

  1. National Institutes of Health [DK076613, HD059122, AI051282, DK071604]
  2. Emory Digestive Diseases Research Center [R24 DK064399]

Ask authors/readers for more resources

Uncontrolled inflammatory responses in the immature gut may play a role in the pathogenesis of many intestinal inflammatory syndromes that present in newborns or children, such as necrotizing enterocolitis (NEC), idiopathic inflammatory bowel diseases (IBD), or infectious enteritis. Consistent with previous reports that murine intestinal function matures over the first 3 weeks of life, we show that inflammatory signaling in the neonatal mouse gut increases during postnatal maturation, with peak responses occurring at 2-3 weeks. Probiotic bacteria can block inflammatory responses in cultured epithelia by inducing the generation of reactive oxygen species (ROS), which inhibit NF-kappa B activation through oxidative inactivation of the key regulatory enzyme Ubc12. We now report for the first time that the probiotic Lactobacillus rhamnosus GG (LGG) can induce ROS generation in intestinal epithelia in vitro and in vivo. Intestines from immature mice gavage fed LGG exhibited increased GSH oxidation and cullin-1 deneddylation, reflecting local ROS generation and its resultant Ubc12 inactivation, respectively. Furthermore, prefeeding LGG prevented TNF-alpha-induced intestinal NF-kappa B activation. These studies indicate that LGG can reduce inflammatory signaling in immature intestines by inducing local ROS generation and may be a mechanism by which probiotic bacteria can prevent NEC in premature infants or reduce the severity of IBD in children. (C) 2009 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available